Terms: = Brain cancer AND NTRK3, TRKC, 4916, ENSG00000140538, Q16288, gp145 trkC
107 results:
1. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
El-Nassan HB; Al-Qadhi MA
Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
[TBL] [Abstract] [Full Text] [Related]
2. Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification.
Gianno F; Giovannoni I; Cafferata B; Diomedi-Camassei F; Minasi S; Barresi S; Buttarelli FR; Alesi V; Cardoni A; Antonelli M; Puggioni C; Colafati GS; Carai A; Vinci M; Mastronuzzi A; Miele E; Alaggio R; Giangaspero F; Rossi S
Pathologica; 2022 Dec; 114(6):422-435. PubMed ID: 36534421
[TBL] [Abstract] [Full Text] [Related]
3. Larotrectinib Response in ntrk3 Fusion-Driven Diffuse High-Grade Glioma.
König D; Hench J; Frank S; Dima L; Bratic Hench I; Läubli H
Pharmacology; 2022; 107(7-8):433-438. PubMed ID: 35526519
[TBL] [Abstract] [Full Text] [Related]
4. LINC02381-ceRNA exerts its oncogenic effect through regulation of IGF1R signaling pathway in glioma.
Nemati H; Fakhre-Taha M; Javanmard AR; Jahanbakhshi A; Mowla SJ; Soltani BM
J Neurooncol; 2022 May; 158(1):1-13. PubMed ID: 35460500
[TBL] [Abstract] [Full Text] [Related]
5. Secretory carcinoma of the salivary gland, a rare entity: An international multi-institutional study.
Wiles AB; Gabrielson M; Baloch ZW; Faquin WC; Jo VY; Callegari F; Kholova I; Song S; Centeno BA; Ali SZ; Tommola S; Fadda G; Petrone G; Wang H; Rossi ED; Pantanowitz L; Maleki Z
Cancer Cytopathol; 2022 Sep; 130(9):684-694. PubMed ID: 35385604
[TBL] [Abstract] [Full Text] [Related]
6. Myoepithelial and oral intracranial myxoid mesenchymal tumor-like neoplasms as diagnostic considerations of the ever-expanding extracranial myxocollagenous tumors harboring FET-CREB fusions.
Lee PH; Kao YC; Hsieh TH; Liao JB; Li CF; Lee JC; Chang YM; Chang CD; Huang SC; Chen TJ; Liu TT; Yu SC; Huang HY
Pathol Res Pract; 2022 Jan; 229():153700. PubMed ID: 34929603
[TBL] [Abstract] [Full Text] [Related]
7. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract] [Full Text] [Related]
8. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
[TBL] [Abstract] [Full Text] [Related]
9. Case of multifocal glioblastoma with four fusion transcripts of
Samii A; Sorokin M; Kar S; Makovskaia L; Garazha A; Hartmann C; Moisseev A; Kim E; Giese A; Buzdin A
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34341009
[TBL] [Abstract] [Full Text] [Related]
10. Secretory carcinoma of the breast with multiple distant metastases in the brain and unfavorable prognosis: a case report and literature review.
Tang H; Zhong L; Jiang H; Zhang Y; Liang G; Chen G; Xie G
Diagn Pathol; 2021 Jun; 16(1):56. PubMed ID: 34162406
[TBL] [Abstract] [Full Text] [Related]
11. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract] [Full Text] [Related]
12. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
Araujo JM; Gomez AC; Pinto JA; Rolfo C; Raez LE
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):192-198. PubMed ID: 33290717
[TBL] [Abstract] [Full Text] [Related]
13. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH
Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984
[TBL] [Abstract] [Full Text] [Related]
14. Balancing neurotrophin pathway and sortilin function: Its role in human disease.
Al-Yozbaki M; Acha-Sagredo A; George A; Liloglou T; Wilson CM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188429. PubMed ID: 32956766
[TBL] [Abstract] [Full Text] [Related]
15. Congenital mesoblastic nephroma is characterised by kinase mutations including EGFR internal tandem duplications, the ETV6-ntrk3 fusion, and the rare KLHL7-BRAF fusion.
Zhao M; Yin M; Kuick CH; Chen H; Aw SJ; Merchant K; Ng EHQ; Gunaratne S; Loh AHP; Gu W; Tang H; Chang KTE
Histopathology; 2020 Oct; 77(4):611-621. PubMed ID: 32590884
[TBL] [Abstract] [Full Text] [Related]
16. Central nervous system ganglioneuroblastoma harboring MYO5A-ntrk3 fusion.
Ito J; Nakano Y; Shima H; Miwa T; Kogure Y; Isshiki K; Yamazaki F; Oishi Y; Morimoto Y; Kataoka K; Okita H; Hirato J; Ichimura K; Shimada H
Brain Tumor Pathol; 2020 Jul; 37(3):105-110. PubMed ID: 32556925
[TBL] [Abstract] [Full Text] [Related]
17. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
18.
Gambella A; Senetta R; Collemi G; Vallero SG; Monticelli M; Cofano F; Zeppa P; Garbossa D; Pellerino A; Rudà R; Soffietti R; Fagioli F; Papotti M; Cassoni P; Bertero L
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979374
[TBL] [Abstract] [Full Text] [Related]
19. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract] [Full Text] [Related]
20. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract] [Full Text] [Related]
[Next]
